IL22 and breast carcinoma: However, despite these various observations implicating the IL-22/IL22R signaling system as a potential marker for aggressive cancer, the precise mechanism by which such an axis promotes the motility of cancer cells and their metastasis at different organ sites has not been definitively identified, especially in metastatic breast cancer.